FDA Approved: BLINCYTO — Original Application (Amgen, Inc)

View source ↗

Summary

The FDA approved BLINCYTO (blinatumomab) from Amgen as an original application. It is a novel bispecific T-cell engager indicated for relapsed/refractory B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

ORIG AP for BLINCYTO (BLINATUMOMAB)